Fibrates are the go-to prescription drug for very high triglycerides. If your triglycerides are sitting in the hundreds and diet, training, and fish oil haven't pulled them down, fenofibrate is the standard next step, and the main reason to take it is to cut your risk of triglyceride-induced pancreatitis.
What fenofibrate is not is a heart-attack-prevention drug. It lowers triglycerides by 30-50% and nudges HDL up, but every large trial that tested whether it actually reduces heart attacks and strokes came back negative, and in 2024 the FDA formally removed cardiovascular risk reduction from its label. If your goal is lowering cardiovascular risk, a 
Statins (atorvastatin, rosuvastatin) is the drug that does that. Fenofibrate has two defensible uses: bringing dangerously high triglycerides out of the pancreatitis danger zone, and slowing diabetic eye disease. For most people reading this, it's a triglyceride tool, not a longevity tool.
Deep-dive
Fenofibrate is a pro-drug. After you swallow it, it's rapidly converted to fenofibric acid, the active molecule, which switches on a receptor called PPAR-alpha in the liver. PPAR-alpha is essentially a master switch for fat burning. When it's activated, the liver ramps up fatty acid oxidation, makes less triglyceride, and changes the way it handles triglyceride-rich particles in the blood.
The triglyceride drop comes from two main levers, both described in this mechanism review. Fenofibrate increases the activity of lipoprotein lipase, the enzyme that strips triglycerides out of circulating particles, and it suppresses apolipoprotein C-III, a protein that normally puts the brakes on that same enzyme. More lipase activity plus less of the brake means triglyceride-rich particles get cleared faster. Activating PPAR-alpha also raises production of apolipoproteins A-I and A-II, which is why HDL goes up.
There's a secondary effect on LDL worth understanding. In people with high triglycerides, LDL particles tend to be small and dense, the kind that are easier to oxidise and slip into the artery wall. As triglycerides come down, LDL particles shift toward being larger and more buoyant, which are cleared more readily. So even when total LDL-C doesn't move much, the particle quality can improve.
Typical lipid changes. In hypertriglyceridemic patients, fenofibrate lowers triglycerides roughly 30-50%, raises HDL-C around 5-20%, and lowers ApoB meaningfully, with one pooled analysis from the TriCor prescribing data showing roughly a 25% ApoB reduction versus placebo. The higher your starting triglycerides, the bigger the absolute drop. LDL-C changes are variable, it can fall in people with ordinary high cholesterol but sometimes rises slightly in people with very high triglycerides as the particles get repackaged.
The cardiovascular outcome trials, and why they matter. This is the part that separates fenofibrate from statins. Three large randomised trials tested whether it prevents cardiovascular events, and the honest summary is that it doesn't. The FIELD trial randomised 9,795 people with type 2 diabetes to fenofibrate or placebo and missed its primary endpoint, fenofibrate did not significantly reduce coronary events. The ACCORD Lipid trial added fenofibrate on top of a statin in 5,518 people with diabetes and also came back negative, with no reduction in heart attack, stroke, or cardiovascular death. Most recently, the PROMINENT trial tested pemafibrate, a newer and more selective fibrate, in nearly 10,500 statin-treated diabetics with high triglycerides, it lowered triglycerides by about 26% but produced zero cardiovascular benefit and was stopped early for futility. On the back of this evidence, the FDA revised the fenofibrate label in 2024 to state plainly that it was not shown to reduce coronary heart disease morbidity or mortality. The takeaway: lowering triglycerides with a fibrate, in isolation, does not appear to lower cardiovascular risk. This is one of the cleaner negative results in cardiology.
There is a recurring caveat. In both FIELD and ACCORD Lipid, a prespecified subgroup, people with both high triglycerides and low HDL at baseline, did appear to benefit, with ACCORD showing roughly a 28-30% reduction in the primary outcome in that group. This is a real signal but it's a subgroup finding, not a trial result, and PROMINENT was essentially designed to test exactly that population and still failed. Treat the dyslipidemic-subgroup benefit as a hypothesis, not a reason to expect cardiovascular protection.
Diabetic retinopathy, the genuinely positive story. While fenofibrate was failing its heart trials, something unexpected showed up in the eye data. Sub-studies of both FIELD and ACCORD found less progression of diabetic retinopathy in the fenofibrate groups, which prompted a trial built specifically to test it. The LENS trial, published in 2024, followed people with early diabetic retinopathy and found fenofibrate reduced progression to referable retinopathy or maculopathy by about 27%. Notably, the lipid changes in LENS were small, which suggests fenofibrate is acting directly inside the eye, on the retinal microvasculature, rather than through its effect on blood lipids. This is now its most evidence-backed use beyond triglyceride lowering, and it's relevant if you have diabetes with early retinal changes.
Kidney effects, in both directions. Fenofibrate reversibly raises serum creatinine, which makes kidney function look slightly worse on paper. In FIELD, creatinine returned to normal within weeks of stopping the drug. Confusingly, the longer-term picture in both FIELD and ACCORD was the opposite, slower decline in kidney function and less albuminuria, suggesting the drug is mildly kidney-protective over time despite the creatinine bump. The practical consequence is that the creatinine rise complicates monitoring and means the dose needs to be lower, or the drug avoided, in people with significant kidney impairment.
Women. Women were included throughout the major trials, FIELD was about 37% women, ACCORD Lipid 31%, and the lipid and retinopathy responses don't differ meaningfully by sex. The negative cardiovascular result applies equally to women. Where sex genuinely matters is in what raises triglycerides in the first place. Oral oestrogen, whether from combined birth control pills, oral hormone replacement therapy, tamoxifen, or clomiphene, increases hepatic VLDL production and can push triglycerides up substantially, occasionally into the pancreatitis range in women who already have an underlying lipid disorder, as described in this Endocrine Society guideline. Transdermal oestrogen largely avoids this because it bypasses first-pass liver metabolism. If you're a woman with high triglycerides on oral oestrogen, switching to a transdermal route is often the first move before reaching for fenofibrate. Fenofibrate is also used to control severe hypertriglyceridemia in women undergoing IVF, where the hormonal stimulation can spike triglycerides sharply. It should not be used during pregnancy or breastfeeding outside of specialist-supervised severe hypertriglyceridemia, the safety data isn't there.
Where fibrates still have a defensible role. Despite the negative cardiovascular trials, fenofibrate isn't obsolete. Severe hypertriglyceridemia, triglycerides above roughly 500 mg/dL and especially above 880 mg/dL, carries a real risk of acute pancreatitis, and bringing those numbers down is a legitimate, urgent goal independent of cardiovascular outcomes. Statins don't lower triglycerides nearly as much. So fenofibrate keeps a clear niche, it's just a narrower one than how it was prescribed for decades.
Dosage:
- Standard dose is 145-160 mg once daily of the standard fenofibrate tablet, or 130-135 mg of the micronised capsule formulations. There is no benefit to splitting the dose, it's a once-daily drug
- Take it at the same time each day. Older formulations needed to be taken with food for absorption, most modern formulations (the 145 mg tablet, the micronised capsules) are absorption-independent and can be taken with or without food. Check which formulation you have
- For severe hypertriglyceridemia, the full 145-160 mg dose is standard from the start. This is the main legitimate use case and the dose isn't titrated gently the way a statin is
- Lower the dose in kidney impairment. Reduced renal function calls for roughly 45-50 mg daily, and fenofibrate is generally avoided in severe kidney disease. The drug reversibly raises creatinine, so kidney function should be checked before starting
- It is frequently combined with high-dose Omega-3 (EPA/DHA, 2-4 g/day) for severe hypertriglyceridemia, the two work through different mechanisms and stack well.
- Combining fenofibrate with a statin is done in practice but adds little, the FDA withdrew the statin co-administration indication because the combination didn't improve outcomes and raised the risk of muscle damage. If both are used, fenofibrate is preferred over gemfibrozil because gemfibrozil interferes with statin metabolism and sharply increases rhabdomyolysis risk
- Women on oral oestrogen with high triglycerides: switching to transdermal oestrogen often lowers triglycerides enough to avoid needing fenofibrate at all. Worth trying first
- No sex-specific dose adjustment otherwise. Do not use during pregnancy or breastfeeding except under specialist supervision for severe hypertriglyceridemia
- Separate fenofibrate from bile acid sequestrants (cholestyramine, colesevelam) by at least 1 hour before or 4-6 hours after, the sequestrant binds it and blocks absorption
Here's what you can expect:
Triglycerides start dropping within the first 2-4 weeks and reach their new level by about 8 weeks. If your starting triglycerides were very high, the absolute fall can be dramatic, several hundred mg/dL. HDL rises modestly over the same period. You won't feel any of this. Fenofibrate produces no noticeable subjective effect, no energy change, no mood change. It's a number-mover, and the blood test is the only way to know it's working.
The diabetic retinopathy benefit, if that's why you're taking it, is invisible and slow, it shows up as slower progression on retinal screening over years, not as anything you'd notice day to day.
Side effects & risks:
- Liver enzyme elevation is the most common issue. Fenofibrate can raise ALT and AST, usually in the first few months, and occasionally enough to require stopping the drug. Rare cases of more serious drug-induced liver injury have been reported. Liver enzymes need checking at baseline and periodically
- Reversible creatinine rise. Fenofibrate raises serum creatinine in a way that looks like worsening kidney function but reverses on stopping. It's not thought to reflect real kidney damage, but it complicates monitoring and means the drug needs dose reduction or avoidance in kidney impairment
- Muscle problems (myopathy, rarely rhabdomyolysis). Fibrates can cause muscle pain and, rarely, serious muscle breakdown. The risk goes up substantially when combined with a statin. With gemfibrozil the statin interaction is dangerous, fenofibrate is safer in combination but the risk isn't zero. Report unexplained muscle pain, tenderness, or weakness, especially with dark urine
- Gallstones. Fenofibrate increases cholesterol excretion into bile, which raises the risk of gallstones over time. This is a known class effect going back to older fibrates
- Pancreatitis, paradoxically, appears in the post-marketing adverse event list even though the drug is used to prevent triglyceride-induced pancreatitis. Rare, but noted
- VTE signal. In PROMINENT, the pemafibrate group had more venous thromboembolism (blood clots in the legs and lungs). Whether this extends to fenofibrate isn't fully established, but it's a class-level signal worth knowing
- Drug interactions. Fenofibrate potentiates warfarin and other vitamin-K-antagonist blood thinners, INR needs closer monitoring. Caution when combined with colchicine (muscle toxicity) and ciclosporin (kidney effects)
- Gastrointestinal upset, headache, and back pain are reported but usually mild
- No established cardiovascular benefit. This isn't a side effect but it belongs in any honest risk discussion: the main reason people historically took this drug, lowering heart attack and stroke risk, is not supported by the trial evidence
- Pregnancy and breastfeeding: avoid outside of specialist-supervised severe hypertriglyceridemia. Safety data is insufficient
Blood markers
Full lipid panel (triglycerides, HDL-C, LDL-C, total cholesterol, non-HDL-C) at baseline and at 8-12 weeks to confirm the triglyceride response, then every 6-12 months once stable. Triglycerides are the marker that actually moves and the reason you're on the drug, so this is the one that matters most.
ApoB at baseline and at 8-12 weeks if cardiovascular risk is part of the picture. Useful because LDL-C can be misleading in people with high triglycerides, and ApoB tells you whether the total atherogenic particle burden is actually improving.
ALT/AST (liver enzymes) at baseline and periodically, this is non-optional. Fenofibrate can raise liver enzymes and occasionally cause real liver injury. The FDA label specifically calls for ongoing liver monitoring.
Serum creatinine and eGFR at baseline and after starting. Fenofibrate reversibly raises creatinine, so you need a reference point, and significant kidney impairment changes the dose or rules the drug out.
Creatine kinase (CK) only if muscle symptoms develop. A baseline is worth having if you're also on a statin or you're an athlete with chronically elevated CK from training.
For most people starting fenofibrate for high triglycerides: a full lipid panel, ALT/AST, and creatinine at baseline, then recheck lipids and liver enzymes at 8-12 weeks. If you have diabetes, keep up with regular retinal screening, that's where the genuine non-lipid benefit shows up.
Fenofibrate is a prescription medication in most countries.
Made with Bullet